- Home
- GNTA vs PSNL Comparison
GNTA vs PSNL Comparison
Compare GNTA & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Italy | United States |
| Employees | 9 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 1.4B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNTA | PSNL |
|---|---|---|
| Price | $0.68 | $16.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 45.3K | ★ 2.7M |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $4.96 |
| 52 Week High | $10.00 | $18.89 |
Technical Indicators
Market Signals| Indicator | GNTA | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 21.67 | 52.56 |
| Support Level | $0.58 | $7.62 |
| Resistance Level | $0.74 | $16.39 |
| Average True Range (ATR) | 0.09 | 0.49 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 5.26 | 17.12 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.